Home LiteratureArticle Details
PMID: 10359567 Published · ppublish English Journal Article Research Support, U.S. Gov't, P.H.S.

Apo E structure determines VLDL clearance and atherosclerosis risk in mice.

The Journal of clinical investigation ·Vol. 103 ·No. 11 ·1999-06-00 ·Pages 1579-86

Knouff C, Hinsdale ME, Mezdour H, Altenburg MK, Watanabe M, Quarfordt SH, Sullivan PM, Maeda N

Abstract

We have generated mice expressing the human apo E4 isoform in place of the endogenous murine apo E protein and have compared them with mice expressing the human apo E3 isoform. Plasma lipid and apolipoprotein levels in the mice expressing only the apo E4 isoform (4/4) did not differ significantly from those in mice with the apo E3 isoform (3/3) on chow and were equally elevated in response to increased lipid and cholesterol in their diet. However, on all diets tested, the 4/4 mice had approximately twice the amount of cholesterol, apo E, and apo B-48 in their VLDL as did 3/3 mice. The 4/4 VLDL competed with human LDL for binding to the human LDL receptor slightly better than 3/3 VLDL, but the VLDL clearance rate in 4/4 mice was half that in 3/3 mice. On an atherogenic diet, there was a trend toward greater atherosclerotic plaque size in 4/4 mice compared with 3/3 mice. These data, together with our earlier observations in wild-type and human APOE*2-replacement mice, demonstrate a direct and highly significant correlation between VLDL clearance rate and mean atherosclerotic plaque size. Therefore, differences solely in apo E protein structure are sufficient to cause alterations in VLDL residence time and atherosclerosis risk in mice.

MeSH Terms
Animals Aorta/pathology Apolipoprotein E2 Apolipoprotein E3 Apolipoprotein E4 Apolipoproteins E/genetics,metabolism Arteriosclerosis/metabolism,pathology Humans Lipoproteins, VLDL/metabolism Mice Mice, Inbred C57BL Risk Factors
Chemicals
Apolipoprotein E2 Apolipoprotein E3 Apolipoprotein E4 Apolipoproteins E Lipoproteins, VLDL
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Knouff C
Department of Pathology and Laboratory Medicine, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina 27599-7525, USA.
Hinsdale M E
Mezdour H
Altenburg M K
Watanabe M
Quarfordt S H
Sullivan P M
Maeda N
References (39)
39 references, click to expand
  1. Hepatic apo E expression is required for remnant lipoprotein clearance in the absence of the low density lipoprotein receptor.
    J Clin Invest. 1998 Apr 15;101(8):1726-36 PMID: 9541504
  2. Phenotype-dependent differences in apolipoprotein E metabolism and in cholesterol homeostasis in human monocyte-derived macrophages.
    J Clin Invest. 1998 Apr 15;101(8):1670-7 PMID: 9541497
  3. Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse Apoe with human Apoe*2.
    J Clin Invest. 1998 Jul 1;102(1):130-5 PMID: 9649566
  4. Lipoprotein clearance mechanisms in LDL receptor-deficient "Apo-B48-only" and "Apo-B100-only" mice.
    J Clin Invest. 1998 Oct 15;102(8):1559-68 PMID: 9788969
  5. Binding and degradation of low density lipoproteins by cultured human fibroblasts. Comparison of cells from a normal subject and from a patient with homozygous familial hypercholesterolemia.
    J Biol Chem. 1974 Aug 25;249(16):5153-62 PMID: 4368448
  6. Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site.
    J Biol Chem. 1982 Mar 10;257(5):2518-21 PMID: 6277903
  7. Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol.
    Clin Chem. 1982 Jun;28(6):1379-88 PMID: 7074948
  8. NIH conference. Type III hyperlipoproteinemia: diagnosis, molecular defects, pathology, and treatment.
    Ann Intern Med. 1983 May;98(5 Pt 1):623-40 PMID: 6846977
  9. Lipoproteins and atherosclerosis. A look back and a look ahead.
    Arteriosclerosis. 1983 Jul-Aug;3(4):283-301 PMID: 6309127
  10. Human apolipoprotein E. Determination of the heparin binding sites of apolipoprotein E3.
    J Biol Chem. 1986 Feb 15;261(5):2068-76 PMID: 2418019
  11. Electron microscopy of negatively stained lipoproteins.
    Methods Enzymol. 1986;128:442-57 PMID: 2425222
  12. Abnormal in vivo metabolism of apolipoprotein E4 in humans.
    J Clin Invest. 1986 Sep;78(3):815-21 PMID: 3745440
  13. Dietary fat clearance in normal subjects is regulated by genetic variation in apolipoprotein E.
    J Clin Invest. 1987 Dec;80(6):1571-7 PMID: 3479440
  14. Simultaneous effects of the apolipoprotein E polymorphism on apolipoprotein E, apolipoprotein B, and cholesterol metabolism.
    Am J Hum Genet. 1988 Jan;42(1):104-12 PMID: 3337104
  15. Quantitative assessment of atherosclerotic lesions in mice.
    Atherosclerosis. 1987 Dec;68(3):231-40 PMID: 3426656
  16. Apolipoprotein E polymorphism and atherosclerosis.
    Arteriosclerosis. 1988 Jan-Feb;8(1):1-21 PMID: 3277611
  17. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology.
    Science. 1988 Apr 29;240(4852):622-30 PMID: 3283935
  18. Characterization of a monoclonal antibody that binds to apolipoprotein E and to lipoprotein of human plasma containing apo E. Applications to ELISA quantification of plasma apo E.
    J Immunoassay. 1988;9(3-4):309-34 PMID: 3235687
  19. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI.
    J Lipid Res. 1990 Mar;31(3):545-8 PMID: 2341813
  20. Opposing effects of apolipoproteins E and C on lipoprotein binding to low density lipoprotein receptor-related protein.
    J Biol Chem. 1990 Jun 25;265(18):10771-9 PMID: 2355022
  21. Influence of apolipoprotein E polymorphism on apolipoprotein B-100 metabolism in normolipemic subjects.
    J Clin Invest. 1991 Nov;88(5):1490-501 PMID: 1939641
  22. Role of apolipoprotein E in hepatic lipase catalyzed hydrolysis of phospholipid in high-density lipoproteins.
    Biochemistry. 1992 Mar 3;31(8):2332-8 PMID: 1540589
  23. Rabbit very low density lipoprotein receptor: a low density lipoprotein receptor-like protein with distinct ligand specificity.
    Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9252-6 PMID: 1384047
  24. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E.
    Science. 1992 Oct 16;258(5081):468-71 PMID: 1411543
  25. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells.
    Cell. 1992 Oct 16;71(2):343-53 PMID: 1423598
  26. Rapid fluorometric assay of LDL receptor activity by DiI-labeled LDL.
    J Lipid Res. 1993 Feb;34(2):325-30 PMID: 8381454
  27. Apolipoprotein E modulates low density lipoprotein retention by lipoprotein lipase anchored to the subendothelial matrix.
    J Biol Chem. 1993 Jul 15;268(20):14812-9 PMID: 8325860
  28. Rapid determination of apolipoprotein E phenotypes from whole plasma by automated isoelectric focusing using PhastSystem and immunofixation.
    J Lipid Res. 1994 Jan;35(1):153-8 PMID: 8138717
  29. Apolipoprotein E: structure-function relationships.
    Adv Protein Chem. 1994;45:249-302 PMID: 8154371
  30. In vivo cholesterol kinetics in apolipoprotein E-deficient and control mice.
    J Lipid Res. 1995 Jun;36(6):1227-35 PMID: 7666000
  31. Prolonged postprandial responses of lipids and apolipoproteins in triglyceride-rich lipoproteins of individuals expressing an apolipoprotein epsilon 4 allele.
    J Clin Invest. 1996 Jan 1;97(1):65-72 PMID: 8550852
  32. Chylomicron assembly and catabolism: role of apolipoproteins and receptors.
    Biochim Biophys Acta. 1996 May 20;1300(3):151-70 PMID: 8679680
  33. Apolipoprotein (apo) E genotype and apoE concentration determine binding of normal very low density lipoproteins to HepG2 cell surface receptors.
    J Lipid Res. 1996 Jun;37(6):1316-24 PMID: 8808766
  34. Method to measure apolipoprotein B-48 and B-100 secretion rates in an individual mouse: evidence for a very rapid turnover of VLDL and preferential removal of B-48- relative to B-100-containing lipoproteins.
    J Lipid Res. 1996 Jan;37(1):210-20 PMID: 8820116
  35. Apolipoprotein E alleles and risk of coronary disease. A meta-analysis.
    Arterioscler Thromb Vasc Biol. 1996 Oct;16(10):1250-5 PMID: 8857921
  36. Close encounters with apolipoprotein E receptors.
    Curr Opin Lipidol. 1996 Oct;7(5):298-302 PMID: 8937520
  37. Apobec-1 and apolipoprotein B mRNA editing.
    Biochim Biophys Acta. 1997 Mar 10;1345(1):11-26 PMID: 9084497
  38. Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis.
    J Biol Chem. 1997 Jul 18;272(29):17972-80 PMID: 9218423
  39. Differential cellular accumulation/retention of apolipoprotein E mediated by cell surface heparan sulfate proteoglycans. Apolipoproteins E3 and E2 greater than e4.
    J Biol Chem. 1998 May 29;273(22):13452-60 PMID: 9593678
Article Info
Journal
The Journal of clinical investigation
Abbr.
J Clin Invest
ISSN
0021-9738
Published
1999-06-00
Pages
1579-86
Language
English
Region
United States
NLM ID
7802877
PMCID
PMC408371
Subset
IM
Grants
NHLBI NIH HHS · R37 HL042630 · United States
NHLBI NIH HHS · HL-42630 · United States
NCI NIH HHS · P30 CA016086 · United States
NCRR NIH HHS · RR-00111 · United States
NHLBI NIH HHS · R01 HL042630 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com